DK1412493T3 - Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer - Google Patents
Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemerInfo
- Publication number
- DK1412493T3 DK1412493T3 DK02763401.3T DK02763401T DK1412493T3 DK 1412493 T3 DK1412493 T3 DK 1412493T3 DK 02763401 T DK02763401 T DK 02763401T DK 1412493 T3 DK1412493 T3 DK 1412493T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- production systems
- promoters
- methods
- lentiviral vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30956901P | 2001-08-02 | 2001-08-02 | |
PCT/US2002/024275 WO2003012054A2 (en) | 2001-08-02 | 2002-08-01 | Methods and compositions relating to improved lentiviral vector production systems |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1412493T3 true DK1412493T3 (da) | 2012-01-09 |
Family
ID=23198746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02763401.3T DK1412493T3 (da) | 2001-08-02 | 2002-08-01 | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer |
Country Status (8)
Country | Link |
---|---|
US (3) | US7629153B2 (da) |
EP (1) | EP1412493B1 (da) |
AT (1) | ATE527347T1 (da) |
AU (1) | AU2002327412A1 (da) |
CA (1) | CA2456169C (da) |
DK (1) | DK1412493T3 (da) |
IL (2) | IL160132A0 (da) |
WO (1) | WO2003012054A2 (da) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
EP1412493B1 (en) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
EP1438075A4 (en) * | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS |
GB0702694D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Vectors |
GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
EP2170938B1 (en) | 2007-06-06 | 2012-04-18 | Research Development Foundation | Rtef-1 variants and the use thereof for inhibition of angiogenesis |
CA2796601C (en) | 2010-04-19 | 2019-03-26 | Research Development Foundation | Rtef-1 variants and uses thereof |
TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
PL2912186T3 (pl) | 2012-10-24 | 2021-06-14 | Platelet Targeted Therapeutics Llc | Leczenie ukierunkowane na płytki krwi |
GB201318804D0 (en) * | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
SG10201810150UA (en) | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
CA2957800A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
CN108289940B (zh) | 2015-08-03 | 2023-01-13 | 美国卫生和人力服务部 | Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途 |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
ES2718192T3 (es) | 2016-02-25 | 2019-06-28 | Provecs Medical Gmbh | Sistema vector inmunoestimulante novedoso |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CN109641063B (zh) | 2016-04-20 | 2022-11-15 | 能源环境和技术研究中心O.A., M.P. | 用于增强pklr的基因表达的组合物和方法 |
EP4049683A1 (en) | 2016-04-29 | 2022-08-31 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
US10675328B2 (en) * | 2017-02-14 | 2020-06-09 | Children's Hospital Medical Center | Compositions and methods for treatment of Gcase related disease states |
AU2018234918B2 (en) | 2017-03-17 | 2023-11-02 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
GB201706394D0 (en) | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
ES2944360T3 (es) * | 2017-10-03 | 2023-06-20 | Abbott Molecular Inc | Ensayo para la detección del virus de la inmunodeficiencia humana (VIH) |
BR112020007157A2 (pt) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
EP3697452A4 (en) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | LENTIVIRAL VECTORS FOR THE ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFICIENCY |
CA3084632A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a |
WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
EP3758682A4 (en) | 2018-02-26 | 2021-12-15 | Antolrx, Inc. | TOLEROGENIC LIPOSOMES AND THEIR PROCEDURES FOR USE |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
US20210348192A1 (en) * | 2018-09-20 | 2021-11-11 | National University Corporation Tokyo Medical And Dental University | Method for increasing lentiviral vector production |
US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
US20220056092A1 (en) | 2018-12-11 | 2022-02-24 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
CN114174327A (zh) | 2019-03-08 | 2022-03-11 | 黑曜石疗法公司 | 用于可调整调控的cd40l组合物和方法 |
CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
EP3976802A1 (en) | 2019-05-28 | 2022-04-06 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
BR112021025022A2 (pt) | 2019-06-12 | 2022-02-22 | Obsidian Therapeutics Inc | Composições de ca2 e métodos para regulação ajustáveis |
WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
AU2020361533A1 (en) | 2019-10-08 | 2022-04-28 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
CN115210250A (zh) | 2020-01-08 | 2022-10-18 | 黑曜石疗法公司 | 用于可调节性调控转录的组合物和方法 |
CA3170369A1 (en) | 2020-03-05 | 2022-04-14 | Michal Shahar | Methods and compositions for treating cancer with immune cells |
CN116194154A (zh) | 2020-08-07 | 2023-05-30 | 太空飞船七有限责任公司 | 使用aav载体的plakophilin-2(pkp2)基因疗法 |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
AU2022326565A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
CA3227108A1 (en) | 2021-08-11 | 2023-02-16 | Xiaomeng HU | Genetically modified primary cells for allogeneic cell therapy |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023114918A1 (en) | 2021-12-16 | 2023-06-22 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4682195A (en) | 1985-09-30 | 1987-07-21 | General Electric Company | Insulated gate device with configured emitter contact pad |
US5019384A (en) | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
NL8603180A (nl) * | 1986-12-15 | 1988-07-01 | Philips Nv | Meerkleurenafbeeldinrichting, voorzien van een beheerinrichting voor kleurselektie. |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
CA2051288C (en) | 1990-09-14 | 2002-02-05 | Robert L. Martuza | Viral targeted destruction of neoplastic cells |
US5885570A (en) | 1991-01-23 | 1999-03-23 | The General Hospital Corporation | Induction of tolerance with modified immunogens |
DE4204650C1 (da) | 1992-02-15 | 1993-07-08 | Hoffmeister, Helmut, Dr., 4400 Muenster, De | |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5912411A (en) | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5705629A (en) | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
GB9525639D0 (en) | 1995-12-15 | 1996-02-14 | Isis Innovation | Improved retroviral vectors |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
WO1998017815A1 (en) | 1996-10-17 | 1998-04-30 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
US6017758A (en) | 1997-02-20 | 2000-01-25 | Vanderbilt University | DMNPE caged nucleic acid and vector |
WO1998039463A2 (en) | 1997-03-06 | 1998-09-11 | Ueberla Klaus | Lentivirus based vector and vector system |
US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
AU741747B2 (en) | 1997-05-13 | 2001-12-06 | University Of North Carolina At Chapel Hill, The | Lentivirus-based gene transfer vectors |
US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
CN1224712C (zh) | 1997-06-04 | 2005-10-26 | 牛津生物医学(英国)有限公司 | 载体 |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
WO1999004026A2 (en) | 1997-07-18 | 1999-01-28 | Chiron Corporation | Lentiviral vectors |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
CN1322137C (zh) | 1997-12-22 | 2007-06-20 | 牛津生物医学(英国)有限公司 | 基于马传染性贫血病毒(eiav)的逆转录病毒载体 |
US20020048805A1 (en) * | 1998-01-16 | 2002-04-25 | Julie C. Johnston | Feline immunodeficiency virus gene therapy vectors |
EP1045921A2 (en) | 1998-01-16 | 2000-10-25 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
US6084063A (en) | 1998-02-06 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitors of allergic reactions |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
WO1999051754A1 (en) | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
FR2777909B1 (fr) * | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
ES2286893T3 (es) | 1998-08-26 | 2007-12-01 | Sturzl, Michael, Prof. Dr. Rer. Nat | Proteina de union a guanilato (gbp-1) como inhibidor de la proliferacion celular. |
AU6139699A (en) | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
WO2000018240A1 (en) | 1998-10-01 | 2000-04-06 | University Of Southern California | Gene delivery system and methods of use |
GB9825524D0 (en) | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
DE19856463B4 (de) | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
EP1165842A4 (en) | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
WO2000066758A1 (en) | 1999-04-29 | 2000-11-09 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
EP1059357A1 (en) * | 1999-06-09 | 2000-12-13 | Universite Pierre Et Marie Curie Paris Vi | Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery |
ES2447115T3 (es) | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
DK1224314T3 (da) * | 1999-10-12 | 2007-05-21 | Inst Nat Sante Rech Med | Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA |
WO2001034843A1 (en) | 1999-11-10 | 2001-05-17 | The Uab Research Foundation | Lentiviral vector transduction of hematopoietic stem cells |
US6218186B1 (en) | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
IL149704A0 (en) | 1999-12-14 | 2002-11-10 | Novartis Ag | Bovine immunodeficiency virus (biv) based vectors |
US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
CA2398790A1 (en) | 2000-01-28 | 2001-08-02 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
AU2001258668A1 (en) | 2000-05-12 | 2001-11-20 | University Of Southern California | Retroviral vectors comprising an enhanced 3' transcription termination structure |
AU2001265190A1 (en) | 2000-05-30 | 2001-12-11 | University Of Rochester | Siv derived lentiviral vector systems |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖rna仲介遺伝子抑制 |
CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
US20040010130A1 (en) | 2001-02-22 | 2004-01-15 | Motoya Katsuki | Recombinant gene containing inverted repeat sequence and utilization thereof |
WO2002087341A1 (en) | 2001-05-01 | 2002-11-07 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (sin) lentiviral vectors |
EP1412493B1 (en) * | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
US20030119770A1 (en) | 2001-08-02 | 2003-06-26 | Zhennan Lai | Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors |
US7919309B2 (en) | 2001-09-13 | 2011-04-05 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
WO2003072788A1 (en) | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
-
2002
- 2002-08-01 EP EP02763401A patent/EP1412493B1/en not_active Expired - Lifetime
- 2002-08-01 AT AT02763401T patent/ATE527347T1/de not_active IP Right Cessation
- 2002-08-01 US US10/209,952 patent/US7629153B2/en not_active Expired - Lifetime
- 2002-08-01 DK DK02763401.3T patent/DK1412493T3/da active
- 2002-08-01 CA CA2456169A patent/CA2456169C/en not_active Expired - Lifetime
- 2002-08-01 WO PCT/US2002/024275 patent/WO2003012054A2/en not_active Application Discontinuation
- 2002-08-01 IL IL16013202A patent/IL160132A0/xx unknown
- 2002-08-01 AU AU2002327412A patent/AU2002327412A1/en not_active Abandoned
-
2004
- 2004-01-29 IL IL160132A patent/IL160132A/en active IP Right Grant
-
2009
- 2009-10-13 US US12/578,346 patent/US8900858B2/en not_active Expired - Lifetime
-
2014
- 2014-10-28 US US14/525,520 patent/US9260725B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1412493A4 (en) | 2005-11-23 |
IL160132A0 (en) | 2004-06-20 |
US20100062524A1 (en) | 2010-03-11 |
ATE527347T1 (de) | 2011-10-15 |
US9260725B2 (en) | 2016-02-16 |
WO2003012054A3 (en) | 2003-11-20 |
CA2456169C (en) | 2012-05-22 |
US8900858B2 (en) | 2014-12-02 |
AU2002327412A1 (en) | 2003-02-17 |
US20030082789A1 (en) | 2003-05-01 |
US7629153B2 (en) | 2009-12-08 |
EP1412493B1 (en) | 2011-10-05 |
US20150203870A1 (en) | 2015-07-23 |
IL160132A (en) | 2012-01-31 |
CA2456169A1 (en) | 2003-02-13 |
WO2003012054A2 (en) | 2003-02-13 |
EP1412493A2 (en) | 2004-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1412493T3 (da) | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer | |
Moroz-Omori et al. | Photoswitchable gRNAs for spatiotemporally controlled CRISPR-Cas-based genomic regulation | |
Moelling et al. | RNase H as gene modifier, driver of evolution and antiviral defense | |
Xie et al. | Novel epigenetic techniques provided by the CRISPR/Cas9 system | |
Ladomery | Aberrant alternative splicing is another hallmark of cancer | |
Park et al. | Staufen‐mediated mRNA decay | |
Garcia et al. | Ago hook and RNA helicase motifs underpin dual roles for SDE3 in antiviral defense and silencing of nonconserved intergenic regions | |
Maillard et al. | Antiviral RNA interference in mammalian cells | |
WO2003029412A3 (en) | Restricted expression lentivial vectors | |
Kushwaha et al. | The replication initiator protein of a geminivirus interacts with host monoubiquitination machinery and stimulates transcription of the viral genome | |
Kranzusch et al. | Assembly of a functional Machupo virus polymerase complex | |
ATE484596T1 (de) | Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom | |
BR112021006844A2 (pt) | métodos para editar um rna alvo e para tratar ou prevenir uma doença ou condição, rna editado ou uma célula hospedeira tendo um rna editado, rna que recruta desaminase, construção, biblioteca, composição, célula hospedeira, e, kit para editar um rna alvo . | |
Cheng et al. | Signatures of host mRNA 5′ terminus for efficient hantavirus cap snatching | |
BRPI0514396A2 (pt) | polipeptìdeos dependentes de vitamina k modificada | |
NO20074654L (no) | Lenteviral-vektorer og deres anvendelse | |
CL2020002704A1 (es) | Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial | |
Valdmanis et al. | The expanding repertoire of circular RNAs | |
Geerts-Dimitriadou et al. | Analysis of the Tomato spotted wilt virus ambisense S RNA-encoded hairpin structure in translation | |
JP2018534937A5 (da) | ||
Berry et al. | Viral suppressors of RNA silencing hinder exogenous and endogenous small RNA pathways in Drosophila | |
Pagano et al. | RNA recognition by the embryonic cell fate determinant and germline totipotency factor MEX-3 | |
Brown et al. | Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector | |
Oliveira et al. | Animal models of mitochondrial DNA transactions in disease and ageing | |
Aurélie et al. | Lentiviral vectors: a powerful tool to target astrocytes in vivo |